In CMML, mutations in genes coding for chromatin modulators (ASXL1 about 40%) and spliceosome components (SRSF2 about 50%) have been shown to negatively affect patients’ prognosis, but their relationship with global DNA methylation is still unknown [50]. This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.